AstraZeneca Works To Replicate China Success In Russia
Executive Summary
AstraZeneca sees similarities with China in the Russian market and is hoping to replicate its success there, says global product and portfolio strategy head Mark Mallon.
You may also be interested in...
Cancer Programs Critical For 'New AstraZeneca' As Price Pressure, Regulatory Changes Loom In 2017
CEO discussed oncology programs crucial to AstraZeneca’s future and was upbeat on US pricing pressure and Brexit as he insisted the company was "rapidly approaching a return to growth."
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.